These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32424294)

  • 1. Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
    Du T; Song Y; Ray A; Chauhan D; Anderson KC
    Leukemia; 2021 Feb; 35(2):550-561. PubMed ID: 32424294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
    Song Y; Park PMC; Wu L; Ray A; Picaud S; Li D; Wimalasena VK; Du T; Filippakopoulos P; Anderson KC; Qi J; Chauhan D
    Leukemia; 2019 Nov; 33(11):2685-2694. PubMed ID: 30962579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.
    Song Y; Ray A; Li S; Das DS; Tai YT; Carrasco RD; Chauhan D; Anderson KC
    Leukemia; 2016 Sep; 30(9):1877-86. PubMed ID: 27118409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-κB signaling.
    Soong RS; Anchoori RK; Roden RBS; Cho RL; Chen YC; Tseng SC; Huang YL; Liao PC; Shyu YC
    BMC Cancer; 2020 May; 20(1):386. PubMed ID: 32375699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
    Cagnetta A; Cea M; Calimeri T; Acharya C; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Zhong MY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2013 Aug; 122(7):1243-55. PubMed ID: 23823317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
    Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
    Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
    Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression.
    De Smedt E; Maes K; Verhulst S; Lui H; Kassambara A; Maes A; Robert N; Heirman C; Cakana A; Hose D; Breckpot K; van Grunsven LA; De Veirman K; Menu E; Vanderkerken K; Moreaux J; De Bruyne E
    Cancer Res; 2018 Mar; 78(5):1155-1168. PubMed ID: 29259009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
    Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
    Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma.
    Yang Y; Chen Y; Saha MN; Chen J; Evans K; Qiu L; Reece D; Chen GA; Chang H
    Leukemia; 2015 Mar; 29(3):715-26. PubMed ID: 25179733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
    Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
    Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.
    Gu C; Lu T; Wang W; Shao M; Wei R; Guo M; Li R; Qiao L; Hu Y; Zhan F; Seckinger A; Hose D; Yang Y
    Leukemia; 2021 Jun; 35(6):1803-1807. PubMed ID: 32901100
    [No Abstract]   [Full Text] [Related]  

  • 15. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
    Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
    Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
    Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
    Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.
    Chauhan D; Singh AV; Aujay M; Kirk CJ; Bandi M; Ciccarelli B; Raje N; Richardson P; Anderson KC
    Blood; 2010 Dec; 116(23):4906-15. PubMed ID: 20805366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
    Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
    Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.
    Wang Q; Zhao D; Xian M; Wang Z; Bi E; Su P; Qian J; Ma X; Yang M; Liu L; Zu Y; Pingali SR; Chen K; Cai Z; Yi Q
    Blood; 2020 Nov; 136(22):2557-2573. PubMed ID: 32582913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.